Page 1 of 2

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 028622/0102 09/673,735 APPLICANT INFORMATION DISCLOSURE CITATION Bernd DORKEN et al. FILING DATE **GROUP ART UNIT** Unassigned December 27, 2000 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** FILING DATE **DOCUMENT** SUB-**EXAMINER** DATE **CLASS** ·· NAME REF IF CLASS INITIAL NUMBER **APPROPRIATE** FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT SUB-CLASS DATE COUNTRY REF **CLASS** YES NUMBER NO 195 31 348 2/27/97 Fed. Republic of Germany Х PKT A1 9/30/92 0 505 908 Europe A2 91/09968 7/11/91 **WIPO** A3iz 5/4/95 **WIPO** 95/11922 A4\_ 11/21/96 **WIPO** 96/36360 A5 ( OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 A6L BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. PKT 35, March, 1994, pg. 510, XP-002076122, abstract. Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology A7 Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997 Sergey M. Kipnyanov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-**8**A 002115487, Wiley-Liss, Inc., 1998 P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. A9 ' 193-197, XP-002076121, Springer-Verlag, 1997 Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40th A10 Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract. **EXAMINER DATE CONSIDERED** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next

communication to applicant.

Page 2 of 2

| Form PTO-14 | 49   | U.S. DEPARTMENT OF COMMERCE  | ATTY. DOCKET NO.   | SERIAL NO.  |  |  |
|-------------|--|--|--|---|--|--|
| (MODIFIED)  |  | PATENT AND TRADEMARK OFFICE  | 028622/0102  | 09/673,735  |  |  |
| •           |  |  | APPLICANT  | <u> </u>  |  |  |
| INFO        | RMATI  | ION DISCLOSURE CITATION  | Bernd DORKEN et al.  |   |  |  |
|             |  | ·  | FILING DATE  | GROUP ART UNIT  |  |  |
|             | (Use se  | everal sheets if necessary)  | December 27, 2000  | Unassigned  |  |  |
|             |  | OTHER DOCUMENTS (Including A   | outhor, Title, Date, Pertinent Pages,  | Etc.)   |  |  |
| PRT         | A11 -  | "National Cancer Institute Sponsored Stu<br>Description of a Working Formulation for | dy of Classifications of Non-Hodgkin's<br>Clinical Usage.", Cancer, vol. 49, pp. 2 | Lymphomas, Summary and 2112-2135, 1982, (Exhibit 1)     |  |  |
|             | A12  | Harald Stein et al., "Die neue WHO-Klass<br>C-2302-C-2309, December, 1999, includi   | sifikation der malignen Lymphome.", De<br>ing English language summary, (Exhib     | eutsches Arzteblatt, vol. 96, pp.<br>it 2)              |  |  |
|             | A13  | Parveen Kumar et al., 3 <sup>rd</sup> Edition, Clinica                               | al Medicine, pp. 369-370, Bailliere Tind   | all, (Exhibit 3)  |  |  |
|             | A14 -  | Jan De Jonge et al., "PRODUCTION AND FRAGMENTS.", Molecular Immunology, v            | vol. 32, No. 17/18, pp. 1405-1412, 199   | 5, (Exhibit 4)  |  |  |
|             | oinant Bispecific Single Chain<br>Lymphoma Model1.", The |  |  |   |  |  |
|             | A16  | Matthias Mack et al., "Biologic Properties (EpCAM) and CD3.", Proceedings of the 6)  | of a Bispecific Single-Chain Antibody<br>National Academy of Science, vol. 92,     | Directed Against 17-1A<br>pp. 7021-7025, 1995, (Exhibit |  |  |
|             |  |  |  |   |  |  |
| ı           |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
| i           |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  | •   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  |   |  |  |
|             |  |  |  | <b>.</b>  |  |  |
| EXAMINER    |  | P. CONTA   | DATE CONSIDERED  | 19/05   |  |  |
| * EXA       | MINER:   | Initial if citation considered, wheth  | ner or not citation is in conforma   | ance with MPEP 609; Draw                                |  |  |
|             |  | h citation if not in conformance and   | I not considered. Include any c  | opy of this form with next                              |  |  |

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE no persons arguifquired to respond to a collection of information unless it contains a valid OMB control

028622-0102

Under the Paperwork Reduction Act of I

Sheet

ct of 186, no pe

2

of

Substitute for form 1449B/P Complete if Known Application Number 09/673,735 INFORMATION DISCLOSURE 12/27/2000 STATEMENT BY APPLICANT Filing Date Bernd DORKEN **First Named Inventor** Date Submitted: March 28, 2005 1642 **Group Art Unit Examiner Name** Larry Ronald Helms (use as many sheets as necessary)

Attorney Docket Number

| U.S. PATENT DOCUMENTS |              |                      |   |  |                              |  |  |
|-----------------------|--------------|----------------------|---|--|------------------------------|--|--|
| Examiner Initials*    |              | U.S. Patent Document |   |  | Date of Publication of       | Pages, Columns, Lines,<br>Where Relevant |  |
|                       | Cite<br>No.1 | Number               | Kind<br>Code <sup>2</sup> (if<br>known) | Name of Patentee or Applicant of<br>Cited Document | Cited Document<br>MM-DD-YYYY | Passages or Relevant<br>Figures Appear   |  |
|                       |              |                      |   |  |                              |  |  |
|                       |              |                      |   | ·  |                              |  |  |
|                       |              |                      |   |  |                              |  |  |

|           |      |                     |               | F                                    | OREIGN PATENT DOCUMEN        |  |  | ,              |
|-----------|------|---------------------|---------------|--------------------------------------|------------------------------|--|--|----------------|
| Examiner  | Cite | For                 | eign Patent C | ocument                              | Name of Patentee or          | Date of Publication of<br>Cited Document | Pages, Columns, Lines,<br>Where Relevant |                |
| Initials* | No.1 | Office <sup>3</sup> | Number⁴       | Kind Code <sup>5</sup><br>(if known) | Applicant of Cited Documents | MM-DD-YYYY                               | Passages or Relevant<br>Figures Appear   | T <sup>®</sup> |
|           |      |                     |               |                                      |                              |  |  |                |
|           |      |                     |               |                                      |                              |  |  |                |
|           |      |                     |               |                                      |                              | ·  |  |                |
|           |      |                     |               |                                      |                              |  |  |                |
|           |      |                     |               |                                      |                              |  | , , , , , , , , , , , , , , , , , , ,    | 1              |
|           |      | -                   |               |                                      |                              | -  |  |                |
|           |      |                     |               |                                      |                              | · · · · · · · · · · · · · · · · · · ·    |  |                |
|           |      |                     |               |                                      |                              |  |  |                |
|           |      |                     |               |                                      |                              |  |  | -              |
|           |      |                     |               |                                      |                              |  |  | *****          |
|           |      |                     |               |                                      |                              |  |  |                |

|                          | NON PATENT LITERATURE DOCUMENTS  |   |
|--------------------------|--|---|
| Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.               | T⁰  |
| D1                       | ANDERSON, P. M., et al., "G19.4(aCD3) x B43(aCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, no. 11, pp. 2826-2834 (1992). |   |
| D2                       | BOHLEN, H., et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, vol. 53, pp. 4310-4314 (1993).  |   |
| D3                       | HAAGEN, I., et al., "Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma", Blood, vol. 84, no. pp. 556-563 (1994).   |   |
| D4                       | HAAGEN, I., et al., "Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic", Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).  |   |
| D5                       | DE GAST, G. C., et al., "Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell Malignancies", J. Hema., vol. 4, pp. 433-437 (1995).   |   |
|                          | No.1  D1  D2  D3   | <ul> <li>Cite No.1</li> <li>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</li> <li>D1 ANDERSON, P. M., et al., "G19.4(αCD3) x B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, no. 11, pp. 2826-2834 (1992).</li> <li>D2 BOHLEN, H., et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, vol. 53, pp. 4310-4314 (1993).</li> <li>D3 HAAGEN, I., et al., "Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma", Blood, vol. 84, no. pp. 556-563 (1994).</li> <li>D4 HAAGEN, I., et al., "Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic", Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).</li> <li>D5 DE GAST, G. C., et al., "Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell</li> </ul> |

| Examiner<br>Signature | P-01 | Date<br>Considered | 7/19 | 05 |
|-----------------------|------|--------------------|------|----|

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1955 no persons are equired to respond to a collection of information unless it contains a valid OMB control

Sheet

Substitute for form 1449B/PTO Complete if Known 09/673,735 **Application Number** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date 12/27/2000 **First Named Inventor** Bernd DORKEN Date Submitted: March 28, 2005 **Group Art Unit** 1642 Larry Ronald Helms **Examiner Name** (use as many sheets as necessary) 028622-0102 2 Attorney Docket Number

|                      |              | NON PATENT LITERATURE DOCUMENTS  |   |
|----------------------|--------------|--|---|
| Examiner<br>nitials* | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | ٦ |
| PKT D6               |              | WEINER, G. J., et al., "Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy", Leukemia and Lymphoma, vol. 16, pp. 199-207 (1995).  | - |
| 1                    | D7           | HAAGEN, I., "Performance of CD3 x CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy",<br>Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995)   |   |
|                      | D8           | HAAGEN, I., et al., "The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2", Blood, vol. 85, no. 11, pp. 3208-3212 (1995).   |   |
|                      | D9           | MACK, M., et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).   |   |
|                      | D10          | KIPRIYANOV, S. M., et al., "Bispecific diabody for lysis of human B-lineage leukemia cells", The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology", p. 29 Thira Santorini, Greece (May 5-7, 1997).      |   |
|                      | D11          | DE JONGE J., et al., "Bispecific antibody treatment of murine B cell lymphoma", Cancer Immunol. Immunother, vol. 45, pp. 162-165 (1997).   |   |
|                      | D12          | KUFER, P., et al., "Construction and biological activity of a recombinanat bispecific single-chain antibody, designed for therapy of minimal residual colorectal cancer", Cancer Immunol. Immunother, vol. 45, pp. 193-197 (1997).                             |   |
|                      | D13          | KIPRIYANOV, S. M., et al., "Bispecific CD3 x CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells", Int. J. Cancer, vol. 77, pp. 763-772 (1998).   | · |

| Examiner<br>Signature | P. 0 ( | MA | Date<br>Considered | 71 | 9 05 |
|-----------------------|--------|----|--------------------|----|------|

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 persons are reported to respond to a collection of information unless it contains a valid OMB control

|                                   | Substitute for form 1449B/PTO HADES |        |      | Complete if Known      |                    |     |  |
|-----------------------------------|-------------------------------------|--------|------|------------------------|--------------------|-----|--|
|                                   | INFORMATION                         | DISCLO | SURE | Application Number     | 09/673,735         |     |  |
| STATEMENT BY APPLICANT            |                                     |        |      | Filing Date            | 12/27/2000         |     |  |
|                                   |                                     |        |      | First Named Inventor   | Bernd DORKEN       |     |  |
|                                   |                                     |        |      | Group Art Unit         | 1642               |     |  |
| (use as many sheets as necessary) |                                     |        |      | Examiner Name          | Larry Ronald Helms |     |  |
| Sheet                             | 1                                   | of     | 2    | Attorney Docket Number | 028622-0102        | - 0 |  |

|                    |              | NON PATENT LITERATURE DOCUMENTS  |                |
|--------------------|--------------|--|----------------|
| Examiner Initials* | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.               | T <sup>6</sup> |
| PKT D1             |              | ANDERSON, P. M., et al., "G19.4(αCD3) x B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells, Blood, vol. 80, no. 11, pp. 2826-2834 (1992). |                |
|                    | D2           | BOHLEN, H., et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, vol. 53, pp. 4310-4314 (1993).  |                |
|                    | D3           | HAAGEN, I., et al., "Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma", Blood, vol. 84, no. pp. 556-563 (1994).   |                |
|                    | D4           | HAAGEN, I., et al., "Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic", Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).  |                |
|                    | D5           | DE GAST, G. C., et al., "Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell Malignancies", J. Hema., vol. 4, pp. 433-437 (1995).   |                |
|                    | D6           | WEINER, G. J., et al., "Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy", Leukemia and Lymphoma, vol. 16, pp. 199-207 (1995).  |                |
|                    | D7           | HAAGEN, I., "Performance of CD3 x CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy", Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995)  |                |
|                    | D8           | HAAGEN, I., et al., "The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2", Blood, vol. 85, no. 11, pp. 3208-3212 (1995).   |                |
|                    | D9           | MACK, M., et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).   |                |
|                    | D10          | KIPRIYANOV, S. M., et al., "Bispecific diabody for lysis of human B-lineage leukemia cells", The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology", p. 29 Thira Santorini, Greece (May 5-7, 1997).                    |                |

| Examiner<br>Signature | pung | Date<br>Considered | 719/05 |
|-----------------------|------|--------------------|--------|
| The second second     |      |                    |        |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995, ne persons are require number.

Substitute for form 1449B/PTO RADEN Complete if Known **Application Number** 09/673,735 INFORMATION DISCLOSURE 12/27/2000 STATEMENT BY APPLICANT Filing Date Bernd DORKEN **First Named Inventor Group Art Unit** 1642 (use as many sheets as necessary) Larry Ronald Helms **Examiner Name** 2 of 2 **Attorney Docket Number** 028622-0102 Sheet

|                       |              | NON PATENT LITERATURE DOCUMENTS  |                |  |  |  |  |  |
|-----------------------|--------------|--|----------------|--|--|--|--|--|
| Examiner<br>Initials* | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | Τ <sup>6</sup> |  |  |  |  |  |
| PKT                   | D11          | DE JONGE J., et al., "Bispecific antibody treatment of murine B cell lymphoma", Cancer Immunol. Immunother, vol. 45, pp. 162-165 (1997).   |                |  |  |  |  |  |
|                       | D12          | KUFER, P., et al., "Construction and biological activity of a recombinanat bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer", Cancer Immunol. Immunother, vol. 45, pp. 193-197 (1997).                              |                |  |  |  |  |  |
|                       | D13          | KIPRIYANOV, S. M., et al., "Bispecific CD3 x CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells", Int. J. Cancer, vol. 77, pp. 763-772 (1998).   |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |
|                       |              | *  |                |  |  |  |  |  |
|                       |              |  |                |  |  |  |  |  |

| Examiner Signature P. O. | Date<br>Considered | 7195 |
|--------------------------|--------------------|------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance/and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.